BYSI vs. ADAG, ORMP, IOBT, CLSD, ETON, ACRS, GNLX, ANIX, ASRT, and MIST
Should you be buying BeyondSpring stock or one of its competitors? The main competitors of BeyondSpring include Adagene (ADAG), Oramed Pharmaceuticals (ORMP), IO Biotech (IOBT), Clearside Biomedical (CLSD), Eton Pharmaceuticals (ETON), Aclaris Therapeutics (ACRS), Genelux (GNLX), Anixa Biosciences (ANIX), Assertio (ASRT), and Milestone Pharmaceuticals (MIST). These companies are all part of the "pharmaceutical preparations" industry.
BeyondSpring (NASDAQ:BYSI) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, community ranking, analyst recommendations, valuation, profitability, earnings, dividends and risk.
Adagene has a consensus price target of $5.00, suggesting a potential upside of 96.08%. Given Adagene's higher possible upside, analysts clearly believe Adagene is more favorable than BeyondSpring.
Adagene has higher revenue and earnings than BeyondSpring.
40.3% of BeyondSpring shares are owned by institutional investors. Comparatively, 9.5% of Adagene shares are owned by institutional investors. 29.3% of BeyondSpring shares are owned by company insiders. Comparatively, 21.2% of Adagene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, BeyondSpring and BeyondSpring both had 2 articles in the media. BeyondSpring's average media sentiment score of 0.00 beat Adagene's score of -0.13 indicating that BeyondSpring is being referred to more favorably in the media.
BeyondSpring received 167 more outperform votes than Adagene when rated by MarketBeat users. However, 78.26% of users gave Adagene an outperform vote while only 66.79% of users gave BeyondSpring an outperform vote.
BeyondSpring has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500. Comparatively, Adagene has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500.
Summary
Adagene beats BeyondSpring on 6 of the 11 factors compared between the two stocks.
Get BeyondSpring News Delivered to You Automatically
Sign up to receive the latest news and ratings for BYSI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BYSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BeyondSpring Competitors List
Related Companies and Tools
